Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $47.50, but opened at $51.80. Zealand Pharma A/S shares last traded at $51.80, with a volume of 130 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZLDPF shares. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Zealand Pharma A/S has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

The business’s 50-day simple moving average is $45.56 and its 200-day simple moving average is $49.57. The company has a market cap of $3.71 billion, a PE ratio of 3.84 and a beta of 0.88. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, August 13th. The company reported $8.61 EPS for the quarter, beating the consensus estimate of $0.14 by $8.47. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. As a group, analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.